2-(3-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)acetonitrile | 1239875-89-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(3-(2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)acetonitrile
• 英文别名: Benzeneacetonitrile, 3-[2-[[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-；2-[3-[2-[4-[4-(2-hydroxyethyl)piperazin-1-yl]anilino]-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]acetonitrile
• CAS: 1239875-89-8
• 化学式: C₂₇H₂₉N₇O
• 分子量: 467.574
• InChiKey: MGCQENKAQXDYRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Pyrrolopyrimidinyl axl kinase inhibitors
  申请人：Vankayalapati Hariprasad

  公开号：US20100204221A1

  公开（公告）日：2010-08-12

  Compounds represented by Formula (I): are useful in treating diseases, such as cancer, that are mediated and/or associated (at least in part) with Axl kinase. The compounds can be formulated as pharmaceutically acceptable compositions for administration to a subject in need thereof.

  由公式（I）表示的化合物在治疗通过Axl激酶介导和/或相关（至少部分相关）的疾病，如癌症方面具有用处。这些化合物可以制备成药学上可接受的组合物，用于给需要的受试者。
• PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS
  申请人：SuperGen, Inc.

  公开号：EP2393814A1

  公开（公告）日：2011-12-14
• METHODS FOR GENERATING AUGMENTED STEM CELL-DERIVED BETA CELLS AND USES THEREOF
  申请人：President and Fellows of Harvard College

  公开号：US20160177268A1

  公开（公告）日：2016-06-23

  Disclosed herein are methods for generating augmented SC-β cells, and isolated populations of augmented SC-β cells for use in various applications, such as cell therapy.
• [EN] PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS<br/>[FR] INHIBITEURS PYRROLOPYRIMIDINYLE DE L'AXI KINASE
  申请人：SUPERGEN INC

  公开号：WO2010090764A1

  公开（公告）日：2010-08-12

  Compounds represented by Formula (I): are useful in treating diseases, such as cancer, that are mediated and/or associated (at least in part) with AxI kinase. The compounds can be formulated as pharmaceutically acceptable compositions for administration to a subject in need thereof.